Search

Your search keyword '"Dahlof, Bjorn"' showing total 35 results
Start Over Author "Dahlof, Bjorn" Publisher elsevier b.v.
35 results on '"Dahlof, Bjorn"'

1. ASCOT-BPLA

Author

Fuchs, Flavio Danni, Gus, Miguel, Ribeiro, Jorge Pinto, Donzelli, Alberto, Malliani, Alberto, Goldstein, Mark R., Duerden, Martin, Dahlof, Bjorn, Sever, Peter, Poulter, Neil, and Wedel, Hans

Published
2006

2. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)

Author

Poulter, Neil R., Wedel, Hans, Dahlof, Bjorn, Sever, Peter S., Beevers, D. Gareth, Caulfield, Mark, Kjeldsen, Sverre E., Kristinsson, Arni, McInnes, Gordon T., Mehlsen, Jesper, Nieminen, Markku, O'Brien, Eoin, Ostergren, Jan, and Pocock, Stuart

Subjects
Hypertension -- Drug therapy, Hypertension -- Complications and side effects, Cardiovascular diseases -- Drug therapy, Cardiovascular diseases -- Patient outcomes, Antihypertensive drugs -- Evaluation
Published
2005

3. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial

Author

Dahlof, Bjorn, Sever, Peter S., Poulter, Neil R., Wedel, Hans, Beevers, D. Gareth, Caulfield, Mark, Collins, Rory, Kjeldsen, Sverre E., Kristinsson Ami McInnes, Gordon T., Mehlsen, Jesper, Nieminen, Markku, O'Brien, Eoin, and Ostergen, Jan

Subjects
Hypertension -- Drug therapy, Antihypertensive drugs -- Evaluation, Antihypertensive drugs -- Dosage and administration
Published
2005

4. Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study

Author

Wachtell, Kristian, Papademetriou, Vasilios, Smith, Gunnar, Gerdts, Eva, Dahlof, Bjorn, Engblom, Erik, Aurigemma, Gerard P., Bella, Jonathan N., Ibsen, Hans, Rokkedal, Jens, and Devereux, Richard B.

Subjects
Hypertension -- Measurement, Hypertension -- Care and treatment, Heart enlargement -- Measurement, Diastole (Cardiac cycle) -- Measurement, Cardiac patients -- Medical examination, Health
Published
2004

5. Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study

Author

Wachtell, Kristian, Dahlof, Bjorn, Rokkedal, Jens, Papademetriou, Vasilious, Nieminen, Markku S., Smith, Gunnar, Gerdts, Eva, Boman, Kurt, Bella, Jonathan N., and Devereux, Richard B.

Subjects
Hypertension -- Drug therapy, Losartan -- Physiological aspects, Heart enlargement -- Development and progression, Cookery for hypertensives -- Drug therapy, Health
Published
2002

6. Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study

Author

Wachtell, Kristian, Palmieri, Vittorio, Olsen, Michael H., Bella, Jonathan N., Aalto, Tapio, Dahlof, Bjorn, Gerdts, Eva, Wright, Jackson T., Jr., Papademetriou, Vasilios, Mogensen, Carl E., Borch-Johnsen, Knut, Ibsen, Hans, and Devereux, Richard B.

Subjects
Albuminuria -- Health aspects, Heart enlargement -- Physiological aspects, Hypertension -- Physiological aspects, Health
Published
2002

9. Diuretics in the LIFE study

Author

Kato, Johji, Eto, Tanenao, Dahlof, Bjorn, Devereux, Richard B., and Kjeldsen, Sverre E.

Published
2004

11. Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: The losartan intervention for endpoint reduction(LIFE) study

Author

Oikarinen, Lasse, Nieminen, Markku S., Toivonen, Lauri, Viitasalo, Matti, Wachtell, Kristian, Papademetriou, Vasilios, Sverker, Jern, Dahlof, Bjorn, Devereux, Richard B., and Okin, Peter M.

Subjects
Cookery for hypertensives -- Research, Hypertension -- Research, Electrocardiography -- Research, Heart enlargement -- Research, Electrocardiogram -- Research, Health
Published
2003

12. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. (Articles)

Author

Sever, Peter S, Dahlof, Bjorn, Poulter, Neil R, Wedel, Hans, Beevers, Gareth, Caulfield, Mark, Collins, Rory, Kjeldsen, Sverre E, Kristinsson, Arni, McInnes, Gordon T, Mehlsen, Jesper, Nieminen, Markku, O'Brien, Eoin, and Ostergren, Jan

Subjects
Cholesterol -- Measurement, Coronary heart disease -- Prevention, Hypertension -- Health aspects, Cookery for hypertensives
Published
2003

13. Losartan for cardiovascular disease in patients with and without diabetes in the LIFE study

Author

Dahlof, Bjorn, Lindholm, Lars H, Fuchs, Flavio Danni, Lapeyre-Mestre, M, Pathak, A, Montastruc, J L, Brown, M J, Cockcroft, J R, Carlsson, Per-Ola, Hjelmesaeth, Joran, Bursztyn, Michael, Bloom, Jeffrey M, Cruickshank, John Malcolm, Hamon, Martial, Wiedermann, Christian J, Lubsen, Jacobus, and Poole-Wilson, Philip A

Subjects
losartan (Medication) -- Evaluation, Hypertension, Cardiovascular diseases -- Patient outcomes, Adrenergic beta blockers -- Evaluation
Published
2002

14. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Author

Dahlof, Bjorn, Devereux, Richard B, Kjeldsen, Sverre E, Julius, Stevo, Beevers, Gareth, de Faire, Ulf, Fyhrquist, Frej, Ibsen, Hans, Kristiansson, Krister, Lederballe-Pedersen, Ole, Lindholm, Lars H, Nieminen, Markku S, Omvik, Per, Oparil, Suzanne, and Wedel, Hans

Subjects
Hypertension -- Drug therapy, Cardiovascular diseases -- Prevention, Heart enlargement, Atenolol -- Evaluation, Losartan -- Evaluation
Published
2002

15. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Author

Lindholm, Lars H, Ibsen, Hans, Dahlof, Bjorn, Devereux, Richard B, Beevers, Gareth, de Faire, Ulf, Fyhrquist, Frej, Julius, Stevo, Kjeldsen, Sverre E, Kristiansson, Krister, Lederballe-Pedersen, Ole, Nieminen, Markku S, Omvik, Per, Oparil, Suzanne, Wedel, Hans, Aurup, Peter, Edelman, Jonathan, and Snapinn, Steven

Subjects
Hypertension -- Drug therapy, Atenolol -- Evaluation, Losartan -- Evaluation, Cardiovascular diseases -- Risk factors, Diabetics
Published
2002

16. Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial

Author

Lindholm, Lars H, Anderson, Harald, Ekbom, Tord, Hansson, Lennart, Lanke, Jan, Dahlof, Bjorn, de Faire, Ulf, Forsen, Kent, Hedner, Thomas, Linjer, Erland, Schersten, Bengt, Wester, P-O, and Moller, Torgil R

Subjects
Hypertension -- Health aspects, Antihypertensive drugs -- Health aspects, Cancer -- Risk factors, ACE inhibitors -- Health aspects, Diuretics -- Health aspects, Calcium channel blockers -- Health aspects, Adrenergic beta blockers -- Health aspects
Published
2001

17. Randomised trial of effects of calcium antagonists compared with diuretics and b-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study

Author

Hansson, Lennart, Hedner, Thomas, Lund-Johansen, Per, Kjeldsen, Sverre Erik, Lindholm, Lars H, Syvertsen, Jan Otto, Lanke, Jan, de Faire, Ulf, Dahlof, Bjorn, and Karlberg, Bengt E

Subjects
Hypertension, Diltiazem -- Evaluation, Diuretics -- Evaluation, Adrenergic beta blockers -- Evaluation, Stroke (Disease) -- Risk factors, Heart attack -- Risk factors
Published
2000

19. Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic...

Author

Devereux, Richard B. and Dahlof, Bjorn

Subjects
*CARDIAC hypertrophy, *DRUG therapy
Abstract

Presents details on the Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement or PRESERVE study. Study's aim of comparing the ability of enalapril and nifedipine in reducing left ventricular mass; Examination of past similar studies; Criteria for the comparison; Morbid events follow-up.

Published
1996
Full Text
View/download PDF

20. 1085-170 Benefits of losartan on preventing stroke in patients with isolated systolic hypertension: A LIFE substudy.

Author

Kjeldsen, Sverre E, Dahlof, Bjorn, Devereux, Richard B, Julius, Stevo, Aurup, Peter, Edelman, Jonathan, Beevers, Gareth, de Faire, Ulf, Fyhrquist, Frej, Ibsen, Hans, Kristianson, Krister, Lederballe-Pedersen, Ole, Lindholm, Lars H, Nieminen, Markku S, Omvik, Per, Oparil, Suzanne, Snapinn, Steven M, Wedel, Hans, and Lyle, Paulette A

Subjects
*LOSARTAN, *STROKE patients, *STROKE prevention, *HYPERTENSION, *THERAPEUTICS, *DRUG efficacy
Published
2004
Full Text
View/download PDF

21. Comparison of Benazepril Plus Amlodipine or Hydrochlorothiazide in High-Risk Patients With Hypertension and Coronary Artery Disease.

Author

Bakris, George, Briasoulis, Alexandros, Dahlof, Bjorn, Jamerson, Kenneth, Weber, Michael A., Kelly, Roxzana Y., Hester, Allen, Tsushung Hua, Zappe, Dion, and Pitt, Bertram

Subjects
*BENAZEPRIL, *AMLODIPINE, *HYDROCHLOROTHIAZIDE, *HYPERTENSION, *BLOOD pressure, *CORONARY disease, *THERAPEUTICS
Abstract

Combination therapy with benazepril 40 mg and amlodipine 10 mg (BDA) has been shown to be more effective than benazepril 40 mg and hydrochlorothiazide (HCTZ) 25 mg (BDH) in reducing cardiovascular (CV) events in high-risk patients with stage 2 hypertension with similar blood pressure reductions. In the present post hoc analysis, we evaluated whether BDA is more effective than BDH for reducing CV events in patients with known coronary artery disease (CAD) at baseline in a subgroup analysis of the Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH) study. The main trial randomized 11,506 patients. Of those, 5,744 received BDA and 5,762 received BDH. Of the 11,506 patients, 5,314 (46%) were classified as having CAD at baseline. The mean patient follow-up period was 35.7 months for the BDA group and 35.6 months for the BDH group. The primary end point was the interval to the first event of composite CV morbidity and mortality. At baseline, significant differences were present between the 5,314 with CAD and the 6,192 without CAD. The patients with CAD had a lower systolic blood pressure and heart rate, a lower incidence of diabetes, and greater incidence of dyslipidemia. However, no baseline differences were found between the randomized BDA and BDH groups. In the patients with CAD, an 18% reduction occurred in the hazard ratio for CV events (primary end point) with BDA versus BDH (p [ 0.0016). In a prespecified secondary analysis of the composite end point, including only CV death, myocardial infarction, and stroke, the hazard ratio in the patients with CAD was reduced by 25% (p[0.0033) in the BDA group compared with the BDH group. BDA was more effective than BDH at comparable blood pressure reductions for reducing CV events in patients, regardless of the presence of CAD. In conclusion, our findings suggest that the combination of BDA should be preferentially used for older patients with high-risk, stage 2 hypertension. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

23. Renal outcomes in hypertensive Black patients at high cardiovascular risk.

Author

Weir, Matthew R, Bakris, George L, Weber, Michael A, Dahlof, Bjorn, Devereux, Richard B, Kjeldsen, Sverre E, Pitt, Bertram, Wright, Jackson T, Kelly, Roxzana Y, Hua, Tsushung A, Hester, R Allen, Velazquez, Eric, and Jamerson, Kenneth A

Subjects
*HEALTH of African Americans, *HYPERTENSION, *BLIND experiment, *BENAZEPRIL, *HYDROCHLOROTHIAZIDE, *AMLODIPINE, *CARDIOVASCULAR diseases, *PATIENTS
Abstract

The ACCOMPLISH trial (Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension) was a 3-year multicenter, event-driven trial involving patients with high cardiovascular risk who were randomized in a double-blinded manner to benazepril plus either hydrochlorothiazide or amlodipine and titrated in parallel to reach recommended blood pressure goals. Of the 8125 participants in the United States, 1414 were of self-described Black ethnicity. The composite kidney disease end point, defined as a doubling in serum creatinine, end-stage renal disease, or death was not different between Black and non-Black patients, although the Blacks were significantly more likely to develop a greater than 50% increase in serum creatinine to a level above 2.6 mg/dl. We found important early differences in the estimated glomerular filtration rate (eGFR) due to acute hemodynamic effects, indicating that benazepril plus amlodipine was more effective in stabilizing eGFR compared to benazepril plus hydrochlorothiazide in non-Blacks. There was no difference in the mean eGFR loss in Blacks between therapies. Thus, benazepril coupled to amlodipine was a more effective antihypertensive treatment than when coupled to hydrochlorothiazide in non-Black patients to reduced kidney disease progression. Blacks have a modestly higher increased risk for more advanced increases in serum creatinine than non-Blacks. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

24. Coronary heart disease benefits from blood pressure and lipid-lowering

Author

Sever, Peter S., Poulter, Neil R., Mastorantonakis, Stylianos, Chang, Choon Lan, Dahlof, Bjorn, and Wedel, Hans

Subjects
*ANTILIPEMIC agents, *BLOOD pressure, *ADRENERGIC beta blockers, *PATIENTS, *HYPERTENSION, *AMLODIPINE, *HEALTH outcome assessment, *CLINICAL trials, *COMPUTER algorithms
Abstract

Abstract: Background: We have reported the benefits of atorvastatin and of an amlodipine-based regimen on coronary heart disease (CHD) events in hypertensive patients in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). We report further analyses on the combined benefits of these interventions. Methods: 19,342 hypertensive patients were randomised to either an amlodipine or an atenolol-based regimen in the ASCOT Blood Pressure-Lowering Arm (BPLA). 10,305 subjects with total cholesterol ≤6.5 mmol/L were further randomised to atorvastatin 10 mg or placebo in the Lipid-Lowering Arm (LLA). Estimates of CHD risk at baseline based on the Framingham algorithm were compared with observed and predicted event rates throughout ASCOT-LLA. Results: Estimated baseline Framingham risk of CHD events was 22.8 per 1000 patient years. After 3.3 years, when the LLA was stopped, the actual CHD event rate had fallen to 4.8 per 1000 patient years—a reduction of 79% in those assigned amlodipine-based treatment and atorvastatin. Conclusions: CHD benefits associated with BP and lipid lowering were larger than predicted by previous observational and trial data. We estimate that compared with pre-trial treatment, treating about 55 patients with the amlodipine-based regimen and atorvastatin would prevent one CHD event per year. [Copyright &y& Elsevier]

Published
2009
Full Text
View/download PDF

33. 812-4 Serum uric acid and ischemic stroke risk among hypertensive patients with left ventricular hypertrophy: The losartan intervention for endpoint reduction in hypertension (LIFE) study.

Author

Kizer, Jorge R, Hoieggen, Aud, Alderman, Michael H, Kjeldsen, Sverre E, Dahlof, Bjorn, Julius, Stevo, Beevers, Gareth, de Faire, Ulf, Fyhrquist, Frej, Ibsen, Hans, Kristiansson, Krister, Lederballe-Pedersen, Ole, Lindholm, Lars H, Nieminen, Marku S, Omvik, Per, Oparil, Suzanne, Wedel, Hans, Edelman, Jonathan M, Snapinn, Steven M, and Devereux, Richard B

Subjects
*SERUM, *URIC acid, *HYPERTENSION, *LEFT ventricular hypertrophy, *LOSARTAN, *THERAPEUTICS, STROKE risk factors
Published
2004
Full Text
View/download PDF

34. 1009-166 Pulse pressure as cardiovascular risk marker during losartan or atenolol based therapy in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE trial).

Author

Gerdts, Eva, Papademetriou, Vasilios, Wachtell, Kristian, Nieminen, Markku, Bjornstad, Hans, Franklin, Stanley, Dahlof, Bjorn, and Devereux, Richard B

Subjects
*CARDIOVASCULAR diseases risk factors, *LOSARTAN, *HYPERTENSION, *ELECTROCARDIOGRAPHY, *LEFT ventricular hypertrophy, *CARDIAC hypertrophy, *PATIENTS
Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results